 U.S.-listed shares of Verona Pharma Plc VRNA, 2.74 rallied about 39 in premarket trading on Tuesday after the company said a Phase 3 clinical trial evaluating nebulized ensifentrine as a treatment for chronic obstructive pulmonary disease met the primary and secondary endpoints. The data support our belief that ensifentrine will change the treatment paradigm for COPD, Verona CEO David Zaccardelli said in a news release. 